These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 3114438)

  • 21. A randomized, comparative study of buserelin with DES/orchiectomy in the treatment of stage D2 prostatic cancer patients.
    Klioze SS; Miller MF; Spiro TP
    Am J Clin Oncol; 1988; 11 Suppl 2():S176-82. PubMed ID: 3149455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nasally administered buserelin inducing complete remission of lung metastases in male breast cancer.
    Vorobiof DA; Falkson G
    Cancer; 1987 Feb; 59(4):688-9. PubMed ID: 3100015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination treatment in M1 prostate cancer.
    Ferrari P; Castagnetti G; Ferrari G; Pollastri CA; Tavoni F; Dotti A
    Cancer; 1993 Dec; 72(12 Suppl):3880-5. PubMed ID: 8252509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
    Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
    Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three-monthly GnRH agonist (buserelin) for prostatic cancer.
    Waxman J; Sandow J; Abel P; Barton C; Keane P; Williams G
    Br J Urol; 1990 Jan; 65(1):43-5. PubMed ID: 2107012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and endocrine effects of the LHR analogue buserelin after subcutaneous implantation of a slow release preparation in prostatic cancer patients.
    Blom JH; Hirdes WH; Schröder FH; de Jong FH; Kwekkeboom DJ; van't Veen AJ; Sandow J; Krauss B
    Urol Res; 1989; 17(1):43-6. PubMed ID: 2493705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pharmacological evaluation of a new 3-month depot preparation of buserelin for prostatic cancer.
    Waxman J; Sandow J; Thomas H; James N; Williams G
    Cancer Chemother Pharmacol; 1989; 25(3):219-20. PubMed ID: 2513141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A review of the Hammersmith Hospital, St. Bartholomew's Hospital, and Institute of Urology studies of buserelin in advanced prostatic cancer.
    Waxman J
    Am J Clin Oncol; 1988; 11 Suppl 1():S16-8. PubMed ID: 3133943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of Buserelin versus conventional antiandrogenic treatment in patients with T2-4NXM1 prostatic cancer. A prospective, randomized multicentre phase III trial. The "Danish Buserelin Study Group".
    Bruun E; Frimodt-Møller C
    Scand J Urol Nephrol; 1996 Aug; 30(4):291-7. PubMed ID: 8908651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?
    Pickles T; Hamm J; Morris WJ; Schreiber WE; Tyldesley S
    BJU Int; 2012 Dec; 110(11 Pt B):E500-7. PubMed ID: 22564197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complete androgen blockade as treatment for advanced prostate cancer: clinical response and side-effects.
    Neri B; Bartalucci S; Pieri A; Gemelli MT; Rizzo M; Bartoletti R; Trippitelli A; Paoletti MC
    Anticancer Res; 1989; 9(1):13-6. PubMed ID: 2495750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
    Debruyne FM
    Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Buserelin as primary therapy in advanced prostatic carcinoma.
    Presant CA; Soloway MS; Klioze SS; Kosola JW; Yakabow AL; Mendez RG; Kennedy PS; Wyres MR; Naessig VL; Ford KS
    Cancer; 1985 Nov; 56(10):2416-9. PubMed ID: 3930064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Buserelin in the treatment of prostatic cancer.
    Roila F
    Biomed Pharmacother; 1989; 43(4):279-85. PubMed ID: 2506941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
    Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
    Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
    [No Abstract]   [Full Text] [Related]  

  • 36. Buserelin treatment of advanced prostatic cancer: a phase II study.
    Veronesi A; Lo Re G; Dal Bo V; Magri MD; Della Valentina M; Talamini R; Merlo A; Francini M; Monfardini S
    Med Oncol Tumor Pharmacother; 1989; 6(4):255-7. PubMed ID: 2515400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of metastatic prostatic cancer.
    Paulson DF
    Urology; 1985 Feb; 25(2 Suppl):49-52. PubMed ID: 3918376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of the LHRH-analogue Buserelin in the treatment of prostatic cancer. A 10-year review on 1522 patients treated in 119 centres on 4 continents.
    de Voogt HJ; Adenauer H; Widdra WG
    Scand J Urol Nephrol Suppl; 1991; 138():131-6. PubMed ID: 1838426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of efficacy and tolerability of Nilutamide and Buserelin in the treatment of advanced prostate cancer.
    Migliari R; Scarpa RM; Campus G; De Lisa A; Zucca I; D'Atri M; Serra A; Usai E
    Arch Ital Urol Nefrol Androl; 1991 Mar; 63(1):147-53. PubMed ID: 1830407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Buserelin treatment of advanced prostatic carcinoma. Long-term follow-up of antitumor responses and improved quality of life.
    Presant CA; Soloway MS; Klioze SS; Yakabow A; Presant SN; Mendez RG; Kennedy PS; Wyres MR; Naessig VL; Todd B
    Cancer; 1987 May; 59(10):1713-6. PubMed ID: 3103904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.